Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of bimekizumab in moderate to severe hidradenitis suppurativa
2017-000892-10Phase 2Completed
- Sponsor
- UCB
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bimekizumab in hidradenitis suppurativa (HS) (3 arms), sponsored by UCB. Primary endpoint: HiSCR clinical response. Started Jul 2017; status: completed.
02
Drugs
bimekizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2017-000892-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000892-10.